Evidence map›Paper›PMID 39692958›Full record

ReviewDiscover oncology2024

Current status of treatment for malignant ovarian sex cord-stromal tumors.

Fang Chunli, Chen Hailin, Zhou Yingying, Xiao Huajing, Xu Boqun

Abstract readReview
In one paragraph

Review in Discover oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Fang Chunli *Department of Gynecology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing City, Jiangsu Province, China.
Chen Hailin *Department of Gynecology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing City, Jiangsu Province, China.
Zhou YingyingDepartment of Gynecology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing City, Jiangsu Province, China.
Xiao HuajingDepartment of Gynecology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing City, Jiangsu Province, China.
Xu BoqunDepartment of Gynecology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing City, Jiangsu Province, China. trilyfcl@126.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignant ovarian sex cord-stromal tumors belong to a specific type of ovarian epithelial carcinoma, and their prognosis is related to the kind of pathology. Unlike epithelial ovarian cancer, most malignant ovarian sex cord-stromal tumors are low-grade malignant and have a good prognosis. Still, they have a tendency to recur in the long term, and the mortality rate of patients after recurrence is high. Surgery is the preferred treatment for malignant ovarian sex cord-stromal tumors with chemotherapy, and other comprehensive treatments. Recurrent and metastatic malignant ovarian sex cord-stromal tumors usually require systemic adjuvant chemotherapy, and hormonal or targeted therapy may be attempted on an individualized basis in cases where chemotherapy fails.

Indexed as

Current treatmentMalignant ovarian sex cord-stromal tumors

Identifiers

PMID39692958
PMCPMC11655733

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.